Pixclara (floretyrosine F 18)
Telix Pharmaceuticals (TLX)
ApprovedSep 11, 2026
Marketer take
A PET agent for telling recurrent glioma apart from treatment-related change, so neuro-oncologists, neuroradiologists and nuclear medicine sites are the audience, with tracer availability and reimbursement shaping adoption.
- Sponsor company
- Telix Pharmaceuticals (TLX)
- Indication
- To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Therapeutic area
- Diagnostic imaging, Oncology
- Event
- FDA approval
- Date
- Sep 11, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?